TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $767,579 | -19.0% | 85,859 | +39.2% | 0.00% | – |
Q2 2023 | $947,466 | -90.2% | 61,684 | -85.7% | 0.00% | – |
Q1 2023 | $9,704,884 | +156.1% | 431,520 | +139.5% | 0.00% | – |
Q4 2022 | $3,788,912 | -63.3% | 180,167 | -57.0% | 0.00% | -100.0% |
Q3 2022 | $10,322,000 | -2.9% | 418,905 | -4.5% | 0.00% | 0.0% |
Q2 2022 | $10,632,000 | -1.3% | 438,814 | +4.9% | 0.00% | 0.0% |
Q1 2022 | $10,777,000 | -6.9% | 418,184 | +12.1% | 0.00% | 0.0% |
Q4 2021 | $11,576,000 | +28.0% | 372,928 | 0.0% | 0.00% | 0.0% |
Q3 2021 | $9,044,000 | +4952.5% | 372,928 | +2932.2% | 0.00% | – |
Q2 2021 | $179,000 | -98.8% | 12,299 | -97.9% | 0.00% | -100.0% |
Q1 2021 | $14,972,000 | -17.7% | 599,599 | -10.2% | 0.00% | -50.0% |
Q4 2020 | $18,193,000 | – | 667,499 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |